Keyphrases
Aggressive non-Hodgkin Lymphoma
33%
Allogeneic
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Autologous Transplantation
16%
Carmustine
100%
Chemotherapy Regimen
33%
Conditioning Regimen
16%
Confidence Interval
16%
Cyclophosphamide
100%
Cyclosporine
16%
Diffuse Alveolar Hemorrhage
16%
Etoposide
100%
Event Probability
16%
Event-free Survival
16%
Follow-up Time
16%
Graft-versus-host Disease (GvHD)
100%
Hematopoietic Cell Transplantation
16%
High Dose
100%
High Risk
16%
HLA-matched Donor
16%
Leukoencephalopathy
16%
Liver Disease
16%
Methylprednisolone
16%
Non-Hodgkin Lymphoma
100%
Non-relapse Mortality
33%
Overall Survival
16%
Preparative Regimen
16%
Previous Chemotherapy
33%
Recurrent Disease
16%
Total Body Irradiation
33%
Venous Disease
16%
Medicine and Dentistry
Acute Graft Versus Host Disease
33%
Autotransplantation
16%
Carmustine
100%
Cell Transplantation
100%
Chemotherapy Regimens
33%
Chronic Graft Versus Host Disease
33%
Conditioning
16%
Cyclophosphamide
100%
Cyclosporine
16%
Drug Megadose
100%
Etoposide
100%
Event Free Survival
16%
Graft Versus Host Reaction
33%
Hematopoietic Cell
100%
Infection
16%
Leukoencephalopathy
16%
Methylprednisolone
16%
Non-Hodgkin Lymphoma
100%
Overall Survival
16%
Patient History of Chemotherapy
33%
Pulmonary Hemorrhage
16%
Recurrent Disease
16%
Vein Occlusion
16%
Whole Body Radiation
33%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Graft Versus Host Disease
50%
Carmustine
100%
Chemotherapy Regimens
50%
Chronic Graft Versus Host Disease
50%
Ciclosporin
25%
Cyclophosphamide
100%
Etoposide
100%
Event Free Survival
25%
Graft Versus Host Reaction
50%
Infection
25%
Leukoencephalopathy
25%
Lung Hemorrhage
25%
Methylprednisolone
25%
Nonhodgkin Lymphoma
100%
Overall Survival
25%
Patient History of Chemotherapy
50%
Recurrent Disease
25%
Vein Occlusion
25%
Immunology and Microbiology
Acute Graft Versus Host Disease
33%
Autotransplantation
16%
Cell Transplantation
100%
Chronic Graft Versus Host Disease
33%
Ciclosporin
16%
Conditioning
16%
Cyclophosphamide
100%
Drug Megadose
100%
Event Free Survival
16%
Graft-Versus-Host Disease
33%
Hematopoietic Cell
100%
Methylprednisolone
16%
Overall Survival
16%